Document Detail

New aspects in lipidology and atherosclerosis.
MedLine Citation:
PMID:  7750049     Owner:  NLM     Status:  MEDLINE    
Recent advances in lipidology and metabolic aspects of atherosclerosis allow detailed coronary artery disease (CAD) risk assessment that is of clinical relevance. Genetic dyslipidemias can be identified in over 75% of CAD patients and include the atherosclerosis susceptibility trait (low density lipoprotein [LDL] pattern B), hyperapobetalipoproteinemia, lipoprotein (a), apo E isoforms, and lipoprotein susceptibility to oxidative damage. The inherited amino acid disorder homocysteinemia is present in approximately 20% of CAD patients and is easily treated. Recent studies have highlighted significant differences in response to diet and drug therapy that can be predicted based on the presence or absence of these traits.
H R Superko
Related Documents :
7691979 - Significance of r wave changes in exercise-induced supraventricular extrasystoles. angi...
19609889 - Thyroid hormone and coronary artery disease: from clinical correlations to prognostic i...
9021059 - Feasibility analysis of a case-based reasoning system for automated detection of corona...
19101229 - Relation of plaque characteristics defined by coronary computed tomographic angiography...
10966129 - Leukocyte counts and concentrations of soluble adhesion molecules as predictors of coro...
16565549 - Outcomes of patients with stable low-risk coronary artery disease receiving medical- an...
10482159 - Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility ...
9524009 - Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase ...
24191329 - The effect of thymoquinone, an active component of nigella sativa, on isoproterenol ind...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  11 Suppl C     ISSN:  0828-282X     ISO Abbreviation:  Can J Cardiol     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-06-19     Completed Date:  1995-06-19     Revised Date:  2008-04-09    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  4C-8C     Citation Subset:  IM    
Lawrence Berkeley Laboratory, University of California, Berkeley Lipid Institute, Sequoia Hospital, Redwood City 94062-2799, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / therapeutic use
Apolipoproteins / blood
Cholesterol, LDL / blood
Coronary Artery Disease / blood*,  etiology,  genetics,  therapy
Disease Susceptibility
Hyperlipoproteinemias / complications,  genetics*,  therapy
Lipoprotein(a) / blood
Lipoproteins / blood*
Risk Factors
Reg. No./Substance:
0/Antilipemic Agents; 0/Apolipoproteins; 0/Cholesterol, LDL; 0/Lipoprotein(a); 0/Lipoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sophisticated primary and secondary atherosclerosis prevention is cost effective.
Next Document:  Pixel or death: experience from clinical trials assessing lipid lowering therapy.